|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 801 PENNSYLVANIA AVENUE, NW |
Address2 | Suite 700 |
| City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 9204-12
|
||||||||
|
6. House ID# 335890000
|
||||||||
| TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Courtney Piron |
Date | 10/21/2024 5:08:53 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
CBO modeling
Drug Pricing
Fiscal year 2024 Appropriations
H.R. 5376, Inflation Reduction Act
H.R. 6363, the Further Continuing Appropriations and Other Extensions Act, 2024
Importation
Value of Medicine
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Executive Office of the President (EOP), Office of Management & Budget (OMB), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Courtney |
Piron |
|
|
|
Sarah |
Durr |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Antitrust Legislation
Bayh-Dole Act
Biopharmaceutical Intellectual Property
BPCIA
Compulsory licenses
Data Exclusivity
H.R. 5376, Inflation Reduction Act
Intellectual Property Issues in Response to coronavirus
Patents
Reasonable Pricing Clause
S. 1128, Ensuring Access to Generic Medications Act (use patents)
Section 101
WTO TRIPS Waiver
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Courtney |
Piron |
|
|
|
Sarah |
Durr |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
21st Century Cures Act 2.0
340B Contract Pharmacy Policy
340B Drug Discount Program
Accelerated Approval
Alternative Funding Programs
Buy American Executive Order
Cancer Moonshot
CBO modeling
Cell, gene and radioligand therapies
Co-pay accumulator programs
COVID-19
Diversity in Clinical Trials
Drug cost and pricing policy issues
Drug Importation and counterfeiting policy issues
Drug shortages policy issues
FDA modernization policy issues
Foreign manufacturing policy issues
Genetically Targeted Technologies
H.R. 1613, The Drug Price Transparency in Medicaid Act
H.R. 198, Drug Pricing Transparency and Accountability Act
H.R. 2534, PROTECT 340B Act of 2023
H.R. 2679, Pharmacy Benefits Manager Accountability Act
H.R. 2880, Protecting Patients Against PBM Abuses Act
H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency
H.R. 4822, Health Care Price Transparency Act of 2023
H.R. 5376, Inflation Reduction Act
H.R. 5378, Lower Costs, More Transparency Act
H.R. 5416, The Give Kids a Chance Act
H.R. 830/S. 1375, HELP Co-pays Act
Health industry vertical integration
Inflation Reduction Act Implementation
Medicaid Payment Reform
Notice of Benefit Payment Parameters (NBPP)
Orphan drug policy issues
Outcomes based contracting/value based arrangements
Patient assistance program policy issues
PDUFA, BSUFA, GDUFA
Pharmaceutical quality
Pharmaceutical supply chain
Pharmacy benefit manager policy issues
Reauthorization of PAHPA
S. 1131, Drug Price Transparency Act
S. 1133, 340B Accountability Act
S. 1246, SMART Prices Act
S. 127, The Pharmacy Benefit Manager Transparency Act of 2023
S. 1339, Pharmacy Benefit Manager Reform Act
S. 1542/H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act
S. 1967, Patients Before Middlemen Act
S. 2837, 340B Accountability Act 2021
S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act
S. 3131/H.R. 5539, ORPHAN Cures Act
S. 476/HR. 5567 The Maintaining Investments in New Innovations (MINI) Act
S. 652/H.R. 2630, Safe Step Act
S. 79/H.R. 1717, Interagency Patent Coordination and Improvement Act of 2023
Step Therapy
The Medicaid VBPs for Patients (MVP) Act
Transparency policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), White House Office, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Courtney |
Piron |
|
|
|
Sarah |
Durr |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
ASP reporting policy issues
CBO modeling
Center for Medicare and Medicaid Innovation (CMMI) policy issues
Drug Pricing
H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act of 2023
H.R. 2666, Medicaid for VBPs for Patients (MVP) Act
H.R. 2880, Protecting Patients Against PBM Abuses Act
H.R. 3285, Fairness for Patient Medications Act
H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency
H.R. 5376, Inflation Reduction Act
Innovative Pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics
Medicaid
Medicaid rebates and waiver policy issues
Medicare Part A, B and D
Medicare Part D Negotiations
Medicare Part D Re-design and out of pocket cap
Outcomes based Contracting/value based arrangements
Patient Cost-Sharing and Smoothing
Reimbursement for cell therapy products
S. 1544/H.R. 1199, Facilitating Access to Innovative Diagnostics (FIND) Act
S. 1967, Patients Before Middlemen Act
S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act
S. 3131/H.R. 5539, ORPHAN Cures Act
S. 476/HR. 5567, The Maintaining Investments in New Innovations (MINI) Act
Transparency policy issues
Value-Based Purchasing (VBP) Rule
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), White House Office, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Courtney |
Piron |
|
|
|
Sarah |
Durr |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Orphan Drug Tax
Pharmaceutical supply chain incentives
R&D Amortization
Restrict deductions of excessive interest of members of financial reporting groups for disproportionate borrowing in the United States (Sec. 163(n) & 163(o))
Tax Treaties
U.S. Corporate Tax
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Courtney |
Piron |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Sarah |
Durr |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Access to Medicines Issues
Biopharmaceutical Innovation Policies
Free Trade Agreements - Intellectual Property and Transparency Provisions
Global Health Issues
India, China and Canada IP and Market Access Issues
International Market Access and Intellectual Property Issues
Pharmaceutical Supply Chain
Pricing and reimbursement policy issues
Quality of Medicines
Regulatory Cooperation
Supply chain and China Task Force policy issues
Tariffs
Trade Policy
US Swiss Trade Relations
WTO IP Waiver
Fiscal year 2024 Appropriations
H.R. 6363, the Further Continuing Appropriations and Other Extensions Act, 2024
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), State - Dept of (DOS), U.S. Agency for International Development (USAID), Health & Human Services - Dept of (HHS), White House Office, Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Courtney |
Piron |
|
|
|
Sarah |
Durr |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
Anti-Trust Reform
Federal Trade Commission's Non-Compete Clause Proposed Rule
Non-competes
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Courtney |
Piron |
|
|
|
Sarah |
Durr |
|
|
|
Courtney |
Lee-Ashley |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Artificial intelligence
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Sarah |
Durr |
|
|
|
Courtney |
Piron |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |